ClinicalTrials.Veeva

Menu

A Study of Evacetrapib in Healthy Japanese Participants

Lilly logo

Lilly

Status and phase

Completed
Phase 1

Conditions

Healthy Volunteers

Treatments

Drug: Evacetrapib

Study type

Interventional

Funder types

Industry

Identifiers

NCT02226653
14627
I1V-JE-EIAY (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to determine if two different dosing strategies for evacetrapib will have essentially the same effect on the body. The study will also explore the effect of a low fat meal on how the body absorbs evacetrapib. This study will last at least 15 weeks, not including screening. Screening is required within 28 days prior to the date of first dosing.

Enrollment

48 patients

Sex

All

Ages

20 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Overtly healthy Japanese, as determined by medical history and physical examination
  • Have a body mass index (BMI) of 18.0 to 29.9 kg/m^2
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion criteria

  • Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have an abnormal supine blood pressure as determined by the investigator
  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Are women who are pregnant or lactating
  • Have used or intend to use over-the-counter, prescription medications, or herbal medicine 14 days prior to enrollment and during the study
  • Have donated blood of more than 400 mL in the last 12 weeks (males) or in the last 16 weeks (females), or any blood donation (including apheresis) within the last 4 weeks
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to abide by alcohol restrictions
  • Are participants who currently smoke more than 10 cigarettes per day or are unwilling to abide by smoking restrictions

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

48 participants in 2 patient groups

Evacetrapib (reference)
Experimental group
Description:
Single oral dose of 1 tablet of evacetrapib on Day 1 of up to three of five periods
Treatment:
Drug: Evacetrapib
Evacetrapib (test)
Experimental group
Description:
Single oral dose of 2 tablets of evacetrapib on Day 1 of up to three of five periods
Treatment:
Drug: Evacetrapib

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems